Wednesday, May 29, 2013

VARIOUS ONCOLOGY NEWS (FROM Oncology time)

*AT ASCO, WE EXPECT NEWS ABOUT AVASTIN ACTIVITY IN GLIOBLASTOMA
*REGORAFENIB, APPROVED BY THE FDA FOR REFRACTORY GIST
IS SAID NOW TO HAVE ACTIVITY REGARDLESS OF THE FORMS OF RESISTANCEFOR GIST.  THIS DRUG BEHAVE LIKE IT DOES NOT MATTER WHAT REFRACTORINESS YOU GOT: "JUST BRING IT ON"

*CAR T CELL, CD19 CHIMERIC ANTIGEN  RECEPTOR (car) ACTIVATE T-CELL ENOUGH TO CAUSE COMPLETE REMISSION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) EVEN IN RELAPSE SETTING.
* A COMBINATION OF RITUXIMAB, VORINOSTAT, AND CLADRIBINE PRODUCED A 100% RESPONSE RATE IN MANTLE CELL LYMPHOMA

*OVARIAN CANCER IS BEING TARGETED BY OUR NEW APPROACH USING "CONJUGATE" DRUGS.  DMUC5754A IS THE NEW EFFECTIVE IMMUNOLOGIC TARGETING OPTION IN THIS DISEASE, CHCK IT OUT!

*REFRACTORY MYELOMA? CALL DARATUMUMAB!  THE FDA GRANTED "BREAKTHROUGH" STATUS TO THIS DRUG REPORTEDLY!
Post a Comment